BioCardia Inc (BioCardia) is a regenerative medicine company. The company's pipeline products include autologous BCDA-01 and NK1R+ Allogeneic BCDA-03 is for the treatment of ischemic heart failure. Autologous BCDA-02 for chronic myocardial ischemic. NK1R+ allogeneic BCDA-04 treats COVID-19 acute respiratory distress syndrome (ARDS). It also offers cell processing and cell delivery enabling products including cardiamp cell processing platform, helix transendocardial biotherapeutic delivery system, morph universal deflectable guide catheter, morph accesspro sheaths, among others. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioCardia Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- BioCardia Inc Company Overview
- BioCardia Inc Company Snapshot
- BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioCardia Inc - Pipeline Analysis Overview
- BioCardia Inc - Key Facts
- BioCardia Inc - Major Products and Services
- BioCardia Inc Pipeline Products by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc Pipeline Products Overview
- CardiALLO - Heart Failure
- CardiALLO - Heart Failure Product Overview
- CardiALLO - Heart Failure Clinical Trial
- CardiAMP - Chronic Myocardial Ischemia
- CardiAMP - Chronic Myocardial Ischemia Product Overview
- CardiAMP - Chronic Myocardial Ischemia Clinical Trial
- CardiAMP - Heart Failure
- CardiAMP - Heart Failure Product Overview
- CardiAMP - Heart Failure Clinical Trial
- CardiAMP - Post Acute Infarction
- CardiAMP - Post Acute Infarction Product Overview
- Fusion Imaging System
- Fusion Imaging System Product Overview
- Helix Transendocardial Delivery System
- Helix Transendocardial Delivery System Product Overview
- Helix Transendocardial Delivery System Clinical Trial
- Morph DNA Steerable Introducer Sheath
- Morph DNA Steerable Introducer Sheath Product Overview
- BioCardia Inc - Key Competitors
- BioCardia Inc - Key Employees
- BioCardia Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- BioCardia Inc, Recent Developments
- Aug 21, 2024: FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
- Jul 30, 2024: Biocardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family
- Jul 25, 2024: Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
- Jul 17, 2024: BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
- Jun 07, 2024: Biocardia Announces United States Patent Issuance On Intramyocardial Delivery Of Cell Aggregates To The Heart Including Minimally Invasive Radial Artery Approach
- Jun 07, 2024: BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
- Mar 12, 2024: BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
- Dec 18, 2023: BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
- Nov 29, 2023: BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
- Nov 14, 2023: Biocardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
- BioCardia Inc Pipeline Products by Equipment Type
- BioCardia Inc Pipeline Products by Indication
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc, Key Facts
- BioCardia Inc, Major Products and Services
- BioCardia Inc Number of Pipeline Products by Development Stage
- BioCardia Inc Pipeline Products Summary by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
- BioCardia Inc Ongoing Clinical Trials Summary
- CardiALLO - Heart Failure - Product Status
- CardiALLO - Heart Failure - Product Description
- CardiALLO - Heart Failure - Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells in Patients with Post-Myocardial Infarction Heart Failure
- CardiAMP - Chronic Myocardial Ischemia - Product Status
- CardiAMP - Chronic Myocardial Ischemia - Product Description
- CardiAMP - Chronic Myocardial Ischemia - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients with Refractory Angina Pectoris and Chronic Myocardial Ischemia: CardiAMP CMI Trial
- CardiAMP - Heart Failure - Product Status
- CardiAMP - Heart Failure - Product Description
- CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure (CardiAMP Heart Failure Trial)
- CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure II Trial
- CardiAMP - Post Acute Infarction - Product Status
- CardiAMP - Post Acute Infarction - Product Description
- Fusion Imaging System - Product Status
- Fusion Imaging System - Product Description
- Helix Transendocardial Delivery System - Product Status
- Helix Transendocardial Delivery System - Product Description
- Helix Transendocardial Delivery System - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care
- Helix Transendocardial Delivery System - Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)
- Helix Transendocardial Delivery System - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure (CardiAMP Heart Failure Trial)
- Morph DNA Steerable Introducer Sheath - Product Status
- Morph DNA Steerable Introducer Sheath - Product Description
- BioCardia Inc, Key Employees
- BioCardia Inc, Subsidiaries
- Glossary
- BioCardia Inc Pipeline Products by Equipment Type
- BioCardia Inc Pipeline Products by Development Stage
- BioCardia Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioDelivery Sciences International Inc
- Leap Therapeutics Inc
- Sentynl Therapeutics Inc
- Juventas Therapeutics Inc
- DiscGenics Inc
